Abstract
Knowledge of epidemiology, genetic etiopathogenesis, diagnostic criteria, and management of familial hypercholesterolemia have increased in the last two decades. Several population studies have shown that familial hypercholesterolemia is more frequent than previously thought, making this entity the most common metabolic disease with monogenic inheritence in the world. Identification of causal heterozygous pathogenic variants in LDLR, APOB, and PCSK9 genes have increased diagnostic accuracy of classical criteria (extreme hypercholesterolemia, personal / family history of premature coronary artery disease or other cardiovascular disease). Genetic screening has been recently introduced in many European countries to detect patients with familial hypercholesterolemia, mainly affected pediatric subjects, asymptomatic or those at the beggining of their disease, with the purpose of increasing surveillance and avoiding complications such as cardiovascular diseases. Cholesterol-lowering drugs should be started as soon as the diagnosis is made. Various combinations between drugs can be used when the goal is not achieved. New therapies, including small interference ribonucleic acids (siRNA) are being tested in different clinical trials.
Keywords: Dyslipidemia, familial hypercholesterolemia, LDLR, acute myocardial infarction, xanthomas, NGS, mutation.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Familial Hypercholesterolemia: Update and Review
Volume: 21
Author(s): Oscar Francisco Chacón Camacho*, Glustein Pozo Molina, Claudia Fabiola Méndez Catalá, Julia Reyes Reali, René Méndez Cruz and Juan Carlos Zenteno
Affiliation:
- Biochemistry Department, Faculty Medicine, National Autonomous University of Mexico, Mexico City,,Mexico
Keywords: Dyslipidemia, familial hypercholesterolemia, LDLR, acute myocardial infarction, xanthomas, NGS, mutation.
Abstract: Knowledge of epidemiology, genetic etiopathogenesis, diagnostic criteria, and management of familial hypercholesterolemia have increased in the last two decades. Several population studies have shown that familial hypercholesterolemia is more frequent than previously thought, making this entity the most common metabolic disease with monogenic inheritence in the world. Identification of causal heterozygous pathogenic variants in LDLR, APOB, and PCSK9 genes have increased diagnostic accuracy of classical criteria (extreme hypercholesterolemia, personal / family history of premature coronary artery disease or other cardiovascular disease). Genetic screening has been recently introduced in many European countries to detect patients with familial hypercholesterolemia, mainly affected pediatric subjects, asymptomatic or those at the beggining of their disease, with the purpose of increasing surveillance and avoiding complications such as cardiovascular diseases. Cholesterol-lowering drugs should be started as soon as the diagnosis is made. Various combinations between drugs can be used when the goal is not achieved. New therapies, including small interference ribonucleic acids (siRNA) are being tested in different clinical trials.
Export Options
About this article
Cite this article as:
Camacho Francisco Chacón Oscar *, Molina Pozo Glustein , Catalá Fabiola Méndez Claudia , Reali Reyes Julia , Cruz Méndez René and Zenteno Carlos Juan , Familial Hypercholesterolemia: Update and Review, Endocrine, Metabolic & Immune Disorders - Drug Targets 2021; 21() . https://dx.doi.org/10.2174/1871530321666210208212148
| DOI https://dx.doi.org/10.2174/1871530321666210208212148 |
Print ISSN 1871-5303 |
| Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Allegations from Whistleblowers
- Publishing Ethics
- Increase Visibility Of Your Article
- Self Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Drug Targets for Obesity and Depression: From Serotonin to Leptin
Current Drug Targets Signal Transduction Therapy of Diabetic Vascular Complication
Current Signal Transduction Therapy Patent Selections
Recent Patents on Cardiovascular Drug Discovery Cocaine and Acute Vascular Diseases
Current Drug Abuse Reviews Novel Inflammatory Indices in Aortic Disease
Current Medicinal Chemistry Resveratrol and Neurodegenerative Diseases: Activation of SIRT1 as the Potential Pathway towards Neuroprotection
Current Neurovascular Research The Right Ventricle: Biologic Insights and Response to Disease
Current Cardiology Reviews The Contribution of Transcriptomics to Biomarker Development in Systemic Vasculitis and SLE
Current Pharmaceutical Design Subject Index To Volume 6
Current Molecular Medicine The Role of 18FDG PET/CT in the Assessment of Endocarditis, Myocarditis and Pericarditis
Current Radiopharmaceuticals Anticoagulant Therapy in Pregnant Patients with Metabolic Syndrome: A Review
Current Pharmaceutical Biotechnology Electrophysiologic Considerations After Sudden Cardiac Arrest
Current Cardiology Reviews Recent Advances in Endocrine Metabolic Immune Disorders Drug Targeting: An Editorial Overview
Endocrine, Metabolic & Immune Disorders - Drug Targets Curcumin: A Dietary Phytochemical for Targeting the Phenotype and Function of Dendritic Cells
Current Medicinal Chemistry Optimized Turmeric Extracts have Potent Anti-Amyloidogenic Effects
Current Alzheimer Research Cognitive Function and the Ageing Process: The Peculiar Role of Mild Thyroid Failure
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Possibility of Enhanced Risk of Retinal Angiogenesis in Athletes with Pre- Existing Retinal Situation Abusing Erythropoietin Doping: A Hypothesis
Current Drug Safety New Agents – Manifold Consequences: The Management of Lung and Colorectal Cancer is Changing
Current Cancer Therapy Reviews Fatty Acid-Mediated Inhibition of Metal Binding to the Multi-Metal Site on Serum Albumin: Implications for Cardiovascular Disease
Current Topics in Medicinal Chemistry Editorial Statins: [Hot Topic: Statins: Effects Beyond Cholesterol Lowering (Guest Editor: Garry X. Shen)]
Current Drug Targets - Cardiovascular & Hematological Disorders





